Eli Lilly Resets Merger Review Clock On $2.4B Deal
Pharmaceutical giant Eli Lilly & Co. has given enforcers more time to review its planned $2.4 billion deal for biopharmaceutical company Dice Therapeutics Inc. and also gave Dice's investors additional time...To view the full article, register now.
Already a subscriber? Click here to view full article